我院伏立康唑致不良反应30例报告分析

发布时间：2018-05-06 01:10

本文选题：伏立康唑 + 药品不良反应　；参考：《中国药房》2015年17期

【摘要】：目的:了解我院应用伏立康唑所致药品不良反应(ADR)发生的特点及一般规律,为临床合理用药提供参考。方法:通过广东省ADR管理平台,在ADR报表统计模块中,以通用名称"伏立康唑"对我院2007-2014年的数据进行检索,导出Excel报表。对伏立康唑致ADR患者的性别、年龄、用药方案(包括给药剂量、途径和天数)、ADR名称、临床表现和处理等进行统计、分析。结果:所收集的30例伏立康唑所致ADR报告中,ADR以消化系统、精神与行为障碍、神经系统和眼睛及其附属器官等损害为主,占77.78%;20例ADR为静脉滴注给药;30例ADR平均发生时间为4.65 d,其中≤1 d发生的有11例;所有的ADR均治愈,无遗留后遗症或死亡。结论:临床应用伏立康唑时,应注意观察ADR的发生,尤其是联用与伏立康唑有相互作用的药物时,更要注意药物剂量调整和ADR监测。有条件时可进行伏立康唑的血药浓度监测,确保用药安全。
[Abstract]:Objective: to understand the characteristics and general rules of ADR induced by Volconazole in our hospital, and to provide reference for rational drug use in clinic. Methods: the data of our hospital from 2007 to 2014 were retrieved by using the general name "Voliconazole" in the ADR report statistical module of Guangdong Province ADR management platform, and the Excel report form was derived. The sex, age, drug regimen (including dosage, route and days of administration), clinical manifestation and treatment of ADR patients induced by Volconazole were analyzed and analyzed. Results: in 30 cases of ADR induced by Volconazole, digestive system, mental and behavioral disorders, nervous system, eyes and accessory organs were the main types of ADRs. The average time of occurrence of ADR was 4.65 days in 30 patients with ADR and 20 cases with ADR, of which 11 cases occurred less than 1 day. All ADR cases were cured without any sequelae or death. Conclusion: it is necessary to observe the occurrence of ADR in clinical application of Veconazole, especially when combined with Volconazole, the dosage adjustment and ADR monitoring should be paid more attention to. In order to ensure the safety of drug use, the plasma concentration of volconazole can be monitored when conditions are available.
【作者单位】：深圳市第二人民医院药学部临床药学科;深圳市眼科医院药剂科;
【基金】：深圳市科技计划项目(No.JCYJ20140414170821258)
【分类号】：R969.3

【参考文献】